Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker MNPR
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 27, 2026 | SCHEDULE 13G | MNPR Monopar Therapeutics Inc. | BlackRock, Inc. | 338,133 | 5.0% | SCHEDULE 13G ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Xiaoying Tian | 313,384 | 4.7% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Saturn V Capital Management LP | 313,384 | 4.7% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Phillip Gross | 324,195 | 4.8% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Robert Atchinson | 324,195 | 4.8% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Adage Capital Management, L.P. | 324,195 | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | MNPR Monopar Therapeutics Inc. | Xiaoying Tian | 345,626 | 5.2% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | MNPR Monopar Therapeutics Inc. | Saturn V Capital Management LP | 345,626 | 5.2% | SCHEDULE 13G ↗ |
| May 13, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Phillip Gross | 424,195 | 6.2% | SCHEDULE 13G/A ↗ |
| May 13, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Robert Atchinson | 424,195 | 6.2% | SCHEDULE 13G/A ↗ |
| May 13, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Adage Capital Management, L.P. | 424,195 | 6.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | RA Capital Healthcare Fund, L.P. | 667,632 | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Rajeev Shah | 667,632 | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Peter Kolchinsky | 667,632 | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | RA Capital Management, L.P. | 667,632 | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 6, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Alexion Pharmaceuticals, Inc. | 522,667 | 7.8% | SCHEDULE 13G/A ↗ |
| Feb 6, 2026 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | AstraZeneca PLC | 522,667 | 7.8% | SCHEDULE 13G/A ↗ |
| Jan 30, 2026 | SCHEDULE 13D/A (amended) | MNPR Monopar Therapeutics Inc. | Michael J. Brown | 124,629 | 1.8% | SCHEDULE 13D/A ↗ |
| Jan 30, 2026 | SCHEDULE 13D/A (amended) | MNPR Monopar Therapeutics Inc. | Robinson Chandler | 307,370 | 4.5% | SCHEDULE 13D/A ↗ |
| Jan 30, 2026 | SCHEDULE 13D/A (amended) | MNPR Monopar Therapeutics Inc. | Tactic Pharma LLC | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 1.11M | 16.7% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Janus Henderson Group PLC | 1.29M | 19.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | RA Capital Healthcare Fund, L.P. | 742,861 | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Rajeev Shah | 742,861 | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Peter Kolchinsky | 742,861 | 9.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | RA Capital Management, L.P. | 742,861 | 9.9% | SCHEDULE 13G/A ↗ |
| Sep 24, 2025 | SCHEDULE 13D/A (amended) | MNPR Monopar Therapeutics Inc. | Michael J. Brown | 338,067 | 5.1% | SCHEDULE 13D/A ↗ |
| Sep 24, 2025 | SCHEDULE 13D/A (amended) | MNPR Monopar Therapeutics Inc. | Thomas V. O'Halloran | 272,026 | 4.1% | SCHEDULE 13D/A ↗ |
| Sep 24, 2025 | SCHEDULE 13D/A (amended) | MNPR Monopar Therapeutics Inc. | Robinson Chandler | 506,199 | 7.5% | SCHEDULE 13D/A ↗ |
| Sep 24, 2025 | SCHEDULE 13D/A (amended) | MNPR Monopar Therapeutics Inc. | Andrew Paul Mazar | 272,026 | 4.1% | SCHEDULE 13D/A ↗ |
| Sep 24, 2025 | SCHEDULE 13D/A (amended) | MNPR Monopar Therapeutics Inc. | Tactic Pharma LLC | 272,026 | 4.1% | SCHEDULE 13D/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 1.01M | 16.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Janus Henderson Group PLC | 1.17M | 19.2% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 1.01M | 16.5% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Janus Henderson Group PLC | 1.13M | 18.6% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | RA Capital Healthcare Fund, L.P. | 620,116 | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Rajeev Shah | 620,116 | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Peter Kolchinsky | 620,116 | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | RA Capital Management, L.P. | 620,116 | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Tang Capital Partners III, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Tang Capital Partners, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Kevin Tang | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Tang Capital Management, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G | MNPR Monopar Therapeutics Inc. | Phillip Gross | 599,195 | 9.9% | SCHEDULE 13G ↗ |
| Feb 12, 2025 | SCHEDULE 13G | MNPR Monopar Therapeutics Inc. | Robert Atchinson | 599,195 | 9.9% | SCHEDULE 13G ↗ |
| Feb 12, 2025 | SCHEDULE 13G | MNPR Monopar Therapeutics Inc. | Adage Capital Management, L.P. | 599,195 | 9.9% | SCHEDULE 13G ↗ |
| Jan 8, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 952,829 | 15.6% | SCHEDULE 13G/A ↗ |
| Jan 8, 2025 | SCHEDULE 13G/A (amended) | MNPR Monopar Therapeutics Inc. | Janus Henderson Group PLC | 1.05M | 17.2% | SCHEDULE 13G/A ↗ |
49 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:46 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances